Researchers discovered the importance of an enzyme that promotes growth of certain lung cancers. Lung cancer is a ...

Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.

January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

Now that the year is underway and a new presidential administration is in place in Washington, let’s consider the environment ...

Revenue in Q4 2024 increased 45% to $13.53 billion driven by volume growth from Mounjaro and Zepbound. Non-incretin revenue(i) grew by 20% compared to Q4 2023. Pipeline ...

Eli Lilly and Co.’s end last year to its PI3Kα inhibitor program didn’t mean the pharma player was giving up on the target – ...

So, it was a healthy start to the year, M&A-wise, for one of the worst-performing sectors of the S&P 500® in 2024. The Health ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on TransMedics Group (TMDX – Research Report), Amgen (AMGN – ...